Neurocrine Biosciences (NBIX) Revenue Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 2.34% |
| 3 | Zoetis | 32.44 Bn | 30.50 Bn | 1.62 Bn | 2.91% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -11.85% |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | -1.62% |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn | 7.85% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn | 42.25% |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | 14.92% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 333.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.25% |
| Dec 31, 2025 | 28.33% |
| Sep 30, 2025 | 27.78% |
| Jun 30, 2025 | 16.49% |
| Mar 31, 2025 | 11.12% |
| Dec 31, 2024 | 21.84% |
| Sep 30, 2024 | 24.72% |
| Jun 30, 2024 | 30.37% |
| Mar 31, 2024 | 22.57% |
| Dec 31, 2023 | 25.05% |
| Sep 30, 2023 | 28.59% |
| Jun 30, 2023 | 2,163.50% |
| Mar 31, 2023 | 35.35% |
| Dec 31, 2022 | 32.05% |
| Sep 30, 2022 | 31.05% |
| Jun 30, 2022 | -93.08% |
| Mar 31, 2022 | 31.28% |
| Dec 31, 2021 | 25.86% |
| Sep 30, 2021 | 14.51% |
| Jun 30, 2021 | -4.46% |